Last Updated: September 17, 2019
- Guerbet has Lipiodol injection available.
- Guerbet has transferred the manufacturing of Lipiodol injection to the US. As of March 2019, Lipiodol Ultra-Fluide is no longer being imported.
- Guerbet had Lipiodol injection in short supply due to manufacturing problems at Jubilant HollisterStier, the manufacturing site in Canada that supplies Lipiodol for Guerbet.[1-2]
- Lipiodol injection, Guerbet, 10 mL vial, NDC 67684-1901-02
Implications for Patient Care
- Ethiodized oil is a lipophilic non-ionic iodinated contrast medium, derived from poppy seed oil. Lipiodol is the only lipophilic non-ionic contrast media approved in the US.[3-4]
- Ethiodized oil is labeled for use in patients undergoing hysterosalpingography or lymphography and for hepatic intra-arterial use for imaging tumors in patients with hepatocellular carcinoma.
- Ethiodized oil is also commonly used in chemoembolization procedures for the treatment of primary and secondary hepatic malignancies.[5-7]
- Guerbet. Personal communication. June 3, July 13, December 16, 2015; February 17, April 26, June 28, September 20, December 12, 2016; March 13, June 20, October 5 and 10, 2017; January 17, April 11, July 17, October 25, 2018; February 7, May 15, July 17, and September 17, 2019.
- Guerbet. Dear Healthcare Professional Letter. June 1, 2015. Available online at http://www.guerbet-us.com/fileadmin/user_upload/usa_home/customer_care_center/documents/June_1__2015_Lipiodol_Guerbet_DHP_Letter.pdf. Accessed June 2, 2015.
- Lipiodol (ethiodized oil) injection product information. Bloomington, IN: Guerbet, April 2014.
- Swanson D, Maywood C. Miscellaneous radiopaque contrast media. II. Hysterosalpingographic contrast media. In: Swanson D, Chilton H, Thrall J, eds. Pharmaceuticals in Medical Imaging. Radiopaque Contrast Media, Radiopharmaceuticals, Enhancement Agents for Magnetic Resonance Imaging and Ultrasound. New York, NY: MacMillan Publishing Co; 1990:227-236.
- American College of Radiology. ACR Appropriateness Criteria. Radiologic Management of Hepatic Malignancy, 2011: http://www.acr.org/~/media/ACR/Documents/AppCriteria/Interventional/RadiologicManagementHepaticMalignancy.pdf. Accessed June 2, 2015.
- Reidy DL, Schwartz JD. Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials-I: hepatic arterial embolization and embolization-based therapies in unresectable hepatocellular carcinoma. Anticancer Drugs. Jun 2004;15(5):427-437.
- Brown DB, Geschwind JF, Soulen MC, Millward SF, Sacks D. Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies. J Vasc Interv Radiol. Feb 2006;17(2 Pt 1):217-223.
Updated September 17, 2019 by Leslie Jensen, PharmD, Drug Information Specialist. Created June 3, 2015 by Erin R. Fox, PharmD, Director, Drug Information Service. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.